In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

Kostas Biliouris, an analyst from BMO Capital, maintained the Buy rating on Prime Medicine, Inc. (PRME – Research Report). The associated price ...

Consult a medical professional for advice. Source: Focus Medica Chronic granulomatous disease (CGD), also known as Bridges–Good syndrome, chronic granulomatous disorder, and Quie syndrome ...

Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Myelodysplastic Syndrome.

Odyssey Therapeutics Inc. has reported new receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors described as potentially useful for the treatment of autoimmune diseases, ...